Before taking Bavencio(Avelumab)

Vigilant monitoring and management are critical due to risks of immune-related toxicity, infusion reactions, and fetal harm.

Essential Warnings and Management

Key precautions for BAVENCIO involve monitoring for immune-mediated adverse reactions, which necessitate early identification and intervention, often with corticosteroids. Severe infusion-related reactions require interruption, slowing, or permanent discontinuation of the infusion. There is a risk of complications in patients who undergo allogeneic hematopoietic stem cell transplantation. When used with axitinib, there is an increased risk of major adverse cardiovascular events and hepatotoxicity. BAVENCIO can cause fetal harm, so effective contraception is required during and for at least one month after treatment.